BACKGROUND/AIMS: Primary biliary cirrhosis (PBC), an autoimmune disease of the liver, is marked by slow progressive destruction of bile ducts. These patients with PBC often undergo orthotopic liver transplantation (OLT). Ischemic bile duct lesion (IBDL) is a major source of morbidity and even mortality after OLT. Cirrhosis of the liver has a higher tolerance to ischemia than a normal liver, but the mechanism remains unknown. Angiogenesis and proliferation of bile duct often responses in bile duct ischemia, which may enhance ischemic tolerance in patients with cirrhosis. METHODOLOGY: To test the hypothesis, a rat model with cirrhosis was established. Biochemical indexes of ischemic severity were measured including total bilirubin (TBIL) and direct bilirubin (DBIL). Immunohistochemical assay was performed for Ki67 (a biomarker for the proliferation of bile duct) and CD34 (a biomarker of angiogenesis). RESULTS: The levels were lower for TBIL and DBIL in the bile duct from rat model with cirrhosis than that from a normal rat after ischemic surgery (P < 0.05). The levels were higher for Ki67 and CD34 from a rat model with cirrhosis than that from a normal rat after ischemic surgery (P < 0.05). CONCLUSIONS: The results suggest that a liver with cirrhosis has a better ischemic tolerance than a normal liver. Angiogenesis and proliferation of bile duct enhances ischemic tolerance in rats with cirrhosis. More research on the pathogenesis of IBDLs is needed for developing more specific preventive or therapeutic strategies.
BACKGROUND/AIMS: Primary biliary cirrhosis (PBC), an autoimmune disease of the liver, is marked by slow progressive destruction of bile ducts. These patients with PBC often undergo orthotopic liver transplantation (OLT). Ischemic bile duct lesion (IBDL) is a major source of morbidity and even mortality after OLT. Cirrhosis of the liver has a higher tolerance to ischemia than a normal liver, but the mechanism remains unknown. Angiogenesis and proliferation of bile duct often responses in bile duct ischemia, which may enhance ischemic tolerance in patients with cirrhosis. METHODOLOGY: To test the hypothesis, a rat model with cirrhosis was established. Biochemical indexes of ischemic severity were measured including total bilirubin (TBIL) and direct bilirubin (DBIL). Immunohistochemical assay was performed for Ki67 (a biomarker for the proliferation of bile duct) and CD34 (a biomarker of angiogenesis). RESULTS: The levels were lower for TBIL and DBIL in the bile duct from rat model with cirrhosis than that from a normal rat after ischemic surgery (P < 0.05). The levels were higher for Ki67 and CD34 from a rat model with cirrhosis than that from a normal rat after ischemic surgery (P < 0.05). CONCLUSIONS: The results suggest that a liver with cirrhosis has a better ischemic tolerance than a normal liver. Angiogenesis and proliferation of bile duct enhances ischemic tolerance in rats with cirrhosis. More research on the pathogenesis of IBDLs is needed for developing more specific preventive or therapeutic strategies.
Entities:
Keywords:
Angiogenesis; bile duct; cirrhosis; ischemia; proliferation
Authors: Aniela Jakubowski; Christine Ambrose; Michael Parr; John M Lincecum; Monica Z Wang; Timothy S Zheng; Beth Browning; Jennifer S Michaelson; Manfred Baetscher; Manfred Baestcher; Bruce Wang; D Montgomery Bissell; Linda C Burkly Journal: J Clin Invest Date: 2005-08-18 Impact factor: 14.808
Authors: Chia-Yi Kuan; Aryn J Schloemer; Aigang Lu; Kevin A Burns; Wei-Lan Weng; Michael T Williams; Kenneth I Strauss; Charles V Vorhees; Richard A Flavell; Roger J Davis; Frank R Sharp; Pasko Rakic Journal: J Neurosci Date: 2004-11-24 Impact factor: 6.167
Authors: Dzmitry Shcharbin; Natallia Shcharbina; Katarzyna Milowska; Francisco Javier de la Mata; Maria Angeles Muñoz-Fernandez; Serge Mignani; Rafael Gomez-Ramirez; Jean-Pierre Majoral; Maria Bryszewska Journal: Int J Pharm Date: 2014-08-01 Impact factor: 5.875
Authors: Eline Vanheule; Anja M Geerts; Jacques Van Huysse; Daphné Schelfhout; Marleen Praet; Hans Van Vlierberghe; Martine De Vos; Isabelle Colle Journal: Int J Exp Pathol Date: 2008-12 Impact factor: 1.925